TKNO - NASDAQ
Alpha Teknova, Inc.
$5.13
-0.97%Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
At a Glance
Live SnapshotAlpha Teknova, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Alpha Teknova, Inc. Balance Sheet
TKNO • NASDAQ
| Alpha Teknova, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
5.9M | 3.7M | 28.5M | 42.2M | 87.5M | 3.3M | 4.1M | |
0.0 | 26.7M | 0.0 | 0.0 | 0.0 | 1.8M | 5.5M | |
5.9M | 30.4M | 28.5M | 42.2M | 87.5M | 5.1M | 9.7M | |
4.6M | 4.3M | 3.9M | 4.3M | 5.9M | 6.6M | 3M | |
4.6M | 4.3M | 3.9M | 4.3M | 4.7M | 4.6M | 2.3M | |
0.0 | 0.0 | 0.0 | 22K | 1.2M | 1.9M | 733K | |
7.1M | 6.8M | 11.6M | 12.2M | 5.4M | 3.6M | 2.6M | |
0.0 | 0.0 | 0.0 | 2.4M | 2.4M | 0.0 | 188K | |
16.9M | 1.3M | 1.6M | 0.0 | 0.0 | 1.1M | 0.0 | |
34.5M | 42.8M | 45.7M | 61.1M | 101.2M | 16.4M | 15.4M | |
NON-CURRENT ASSETS | |||||||
55.8M | 61.5M | 66.8M | 71.3M | 29.8M | 10M | 5.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 16.6M | 16.6M | 16.6M | |
11.9M | 13.1M | 14.2M | 17.6M | 18.7M | 19.9M | 21M | |
11.9M | 13.1M | 14.2M | 17.6M | 35.3M | 36.5M | 37.6M | |
1.3M | 1.4M | 1.9M | 2.3M | 180K | 24K | 32K | |
69.1M | 76M | 82.9M | 91.1M | 65.3M | 46.5M | 43.1M | |
103.6M | 118.8M | 128.6M | 152.3M | 166.5M | 62.9M | 58.5M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
1.4M | 825K | 1.5M | 2.4M | 2.2M | 1.6M | 768K | |
1.4M | 825K | 1.5M | 2.4M | 2.2M | 1.6M | 768K | |
0.0 | 4.5M | 5.6M | 6M | 5.3M | 1.5M | 3M | |
1.9M | 4M | 0.0 | 0.0 | 0.0 | 0.0 | 45K | |
0.0 | 1.8M | 1.8M | 2.2M | 0.0 | 0.0 | 0.0 | |
0.0 | 30K | 16K | 198K | 200K | 0.0 | 0.0 | |
4.3M | 0.0 | 0.0 | 0.0 | 0.0 | 845K | 1.7M | |
7.5M | 11.2M | 8.9M | 10.9M | 7.7M | 4M | 5.6M | |
NON-CURRENT LIABILITIES | |||||||
13.3M | 9.4M | 13.3M | 22M | 11.9M | 0.0 | 0.0 | |
879K | 827K | 919K | 1.2M | 3.2M | 6M | 3.9M | |
13.1M | 10K | 102K | 191K | 542K | 554K | 36.1M | |
27.3M | 25.2M | 29.7M | 41.5M | 15.6M | 6.5M | 40M | |
0.0 | 16.7M | 17.2M | 20.3M | 0.0 | 0.0 | 0.0 | |
34.8M | 36.4M | 38.6M | 52.4M | 23.3M | 10.5M | 45.6M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 35.6M | 35.6M | |
1K | 1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 200.9M | 181.8M | 154.9M | 150.7M | 14.5M | 14.2M | |
-135.8M | -118.5M | -91.8M | -55M | -7.5M | 2.3M | -1.3M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7K | 20K | |
204.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -35.6M | |
68.8M | 82.4M | 90M | 99.9M | 143.2M | 52.4M | 12.9M | |
68.8M | 82.4M | 90M | 99.9M | 143.2M | 52.4M | 12.9M | |
SUMMARY | |||||||
103.6M | 118.8M | 128.6M | 152.3M | 166.5M | 62.9M | 58.5M | |
0.0 | 26.7M | 0.0 | 0.0 | 0.0 | 1.8M | 5.5M | |
15.1M | 30.2M | 30.5M | 42.3M | 11.9M | 0.0 | 45K | |
9.2M | 26.5M | 2M | 74K | -75.6M | -3.3M | -4.1M | |
53,515,167 | 53,515,167 | 53,515,167 | 53,515,167 | 53,515,167 | 53,515,167 | 53,515,167 |
SEC Filings
TKNO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | May 27, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 08, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 |
Related Guides
Continue your TKNO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.